NCT00219219View on ClinicalTrials.gov

Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases

PHASE4CompletedINTERVENTIONAL
Timeline

Start Date

September 30, 2003

Study Completion Date

October 31, 2006

Conditions
Prostate Cancer
Interventions
DRUG

Zoledronic acid

Trial Locations (1)

Unknown

Bologna, Bologna

Sponsors

Lead Sponsor

Novartis
All Listed Sponsors
collaborator

Società Italiana di Urologia (SIU)

OTHER

lead

Novartis

INDUSTRY